Infections rose amid the COVID-19 pandemic, with a concerning increase in community-onset cases and newer mechanisms of resistance.
Monoclonal antibodies and fecal microbiota-based products are changing the landscape for patients with recurrent Clostridioides difficile infection.
Join CIDRAP-ASP and The AMR Narrative on Tuesday, October 17, for an interactive chat on X (formerly Twitter) on breaking down the science of antimicrobial resistance (AMR) for patients and the public.
True stories from scientists and pateients.
You can find all of CIDRAP-ASP's previous webinars on our YouTube channel.
Take the latest edition of our monthly quiz.
Help support our work on antimicrobial stewardship.
Be in the know about antimicrobial stewardship.
Our antimicrobial resistance factsheet
Antimicrobial resistance occurs when microbes, such as bacteria, evolve the ability to survive exposure to medicines previously used to treat them. Visit the antimicrobial resistance factsheet to learn more.
The Antimicrobial Resistance Toolkit
We developed a toolkit aimed at community practitioners and patients to provide basic information on antimicrobial resistance and responsible use of antibiotics. You can view and download the Toolkit here.
One Health Antimicrobial Stewardship
New open-source teaching module on the Antimicrobial Resistance Learning Site: Judicious Use of Antimicrobials on a Dairy Operation. Designed for veterinarians and veterinary students, the module includes two case-based scenarios about judicious antimicrobial drug use when treating common diseases in dairy cattle.
This review evaluates factors along the wastewater pathway that may contribute to the emergence or worsening of antibiotic-resistant bacteria, along with challenges and opportunities related to the effectiveness of wastewater treatment strategies and regulations on AMR in the environment.
This article on the implications of vaccines on AMR delves into who is most likely to benefit from bacterial vaccines, the challenges that AMR and antigen identification pose to vaccine development, and current and investigational vaccine development platforms.
This literature review assessed two studies that directly estimated AMR costs averted due to pneumococcal vaccine use in China and Ethiopia, as well as a series of cost-effectiveness studies for immunization in the context of AMR, for vaccines in development and under license as of June 1, 2022.
